Tulavi Therapeutics

Tulavi Therapeutics develops innovative surgical solutions for peripheral nerve surgery, specifically addressing the widespread problem of neuroma pain and chronic post-operative pain following nerve injuries and amputations. The company's flagship product, allay™ Hydrogel Cap, is the first fully absorbable technology indicated to reduce the risk of symptomatic neuroma formation. Built on a proprietary hydrogel platform proven safe in over 5 million patients worldwide, allay™ provides surgeons with an intraoperative solution that conforms instantly to each nerve without sutures, reducing operative time and improving patient outcomes. The hydrogel composition is 90% water and forms in situ for consistent results. Tulavi targets orthopedic surgeons, plastic surgeons, and peripheral nerve specialists managing limb loss, revision amputations, and neuroma excision procedures. The company addresses a substantial clinical need: over 550,000 amputations occur annually in the U.S., with 50% of patients experiencing chronic phantom or neuroma pain, and approximately 1.8 million peripheral nerve surgeries annually result in persistent post-operative pain in a significant patient subset.